
News|Articles|February 13, 2019
Yupelri for Chronic Obstructive Pulmonary Disease
Author(s)Drew Boxler
Advertisement
Yupelri (revefenacin, Mylan®)
Indications: Patients with chronic obstructive pulmonary disease
Dosage: One 175 mcg vial (3 mL) once daily.
Contraindications: hypersensitivity to revefenacin or any component of this product.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Long-Term Adverse Effects After COVID-19 Vaccination Vary by Brand
2
Meta-Analysis Identifies 5 Risk Factors for Post-COVID-19 Condition
3
Model Finds Weight Regain After Stopping Semaglutide or Tirzepatide
4
Investigational Oral AD109 Reduces Sleep Apnea Severity by 44%
5







































